Quick Take
- Ultrahuman is in talks to raise about $60 Mn (Rs 575 Cr), led by Steadview and Blume Ventures.
- The round could value the Bengaluru smart-ring maker at $360-400 Mn (Rs 3,450-3,833 Cr) post-money.
- Fresh capital would fund the US re-entry with Ring PRO after the Oura patent setback of 2025.
In This Article
Ultrahuman funding talks are underway for about $60 Mn (Rs 575 Cr), led by existing investors Steadview Capital and Blume Ventures, people aware of the matter said in July 2026.
The round could value the Bengaluru-based smart-ring maker at $360-400 Mn (Rs 3,450-3,833 Cr) on a post-money basis. The final size, terms, and investor mix may change as talks progress. It is being structured as a continuation of the $35-40 Mn round the company closed in March 2026, per the same people. Ultrahuman confirms its US return on its official product site.
StartupFeed Insight
The gap between numbers tells the real story. SoftBank and WestBridge Capital had separately evaluated Ultrahuman at about $500-550 Mn, yet these talks sit near $360-400 Mn. That markdown is the price of the Oura patent fight, which made US institutional capital cautious. Existing backers stepping in signals conviction that the redesigned Ring PRO clears the legal risk. Founders in hardware should watch this closely: a strong revenue run-rate does not fully offset regulatory overhang in a buyer’s market. Expect Ultrahuman to close this round by the end of Q2 FY27, then chase a larger growth round once US sales stabilise. By Avinash.
Ultrahuman Funding Talks: Deal Breakdown
Ultrahuman funding talks target roughly $60 Mn (Rs 575 Cr) in fresh equity, according to people aware of the discussions. The table below sets out the known terms, with figures still subject to change as the deal firms up.
| Metric | Detail | Notes |
|---|---|---|
| Target Raise | ~$60 Mn (Rs 575 Cr) | Size may change as talks progress |
| Lead Investors | Steadview Capital, Blume Ventures | Both are existing backers |
| Post-Money Valuation | $360-400 Mn (Rs 3,450-3,833 Cr) | People aware of the matter |
| Round Structure | Continuation of March round | Extends the $35-40 Mn March 2026 round |
| Earlier Interest | SoftBank, WestBridge Capital | Evaluated at ~$500-550 Mn value |
| Report Date | July 2026 | Talks confirmed by people aware |
The most striking detail is the valuation spread. SoftBank and WestBridge weighed a $500-550 Mn value, well above the current $360-400 Mn talks, per people aware of the discussions.
About Ultrahuman
Ultrahuman is a Bengaluru health technology company that makes the Ring AIR smart ring, the M1 continuous glucose monitor, and Blood Vision testing services. Founded in 2019 by Mohit Kumar and Vatsal Singhal, it operates at the intersection of fitness, healthcare, and consumer technology. Per Wikipedia, its backers include Steadview Capital, Nexus Venture Partners, Blume Ventures, and Alpha Wave Incubation.
Why are Steadview and Blume backing Ultrahuman again?
Steadview Capital and Blume Ventures are backing Ultrahuman again because both have deep prior stakes and now bet on its US comeback. Steadview joined the Series A and co-led the Series B, while Blume has backed the company since its seed round, per public funding records. Their return during a cautious market points to conviction in the redesigned product.
The entire design of Ring PRO has been done from the ground up to make sure there is no patent infringement, a senior Ultrahuman executive said.
That quote frames the thesis. Ultrahuman rebuilt the ring’s internal battery structure, the exact point Oura challenged, to avoid a repeat legal block. For existing investors, clearing that risk protects the value they already hold.
How will Ultrahuman use the funds?
Ultrahuman will use the fresh capital mainly to fund its return to the United States with the redesigned Ring PRO. The company also plans to expand into new geographies and build new wearable categories, including wrist-based devices and home health products, a senior executive said. A US executive earlier confirmed the company received official approval to sell its redesigned ring stateside.
The US market matters because it is the largest single arena for premium wearables. Ultrahuman’s Ring AIR was barred there after the 2025 ruling, so regaining access reopens a major revenue stream. New product lines then widen the base beyond a single ring.
How does Ultrahuman compare with Oura and Whoop?
Ultrahuman competes directly with Finland’s Oura and US-based Whoop in the premium health-wearable sector. The table below compares the three on core positioning.
| Company | Core Device | HQ |
|---|---|---|
| Ultrahuman | Ring AIR / Ring PRO | Bengaluru, India |
| Oura | Oura Ring | Oulu, Finland |
| Whoop | Whoop Band | Boston, US |
What sets Ultrahuman apart is its wider stack. Beyond the ring, it links glucose monitoring, blood testing, and home sensors into one system, while Oura and Whoop stay closer to a single device.
What’s Next
Watch for a formal close on this round in the coming months, with the final size and investor list still open. A confirmed valuation would set a fresh benchmark for Indian wearable startups and test appetite for hardware bets in a tighter market. Ultrahuman’s US sales run over the next two quarters will show whether the reset holds. Will investors reward the comeback, or wait for proof from the US shelves?
Frequently Asked Questions
Disclaimer: This article is for informational purposes only and does not constitute investment advice. StartupFeed and its authors are not SEBI-registered investment advisors. The analysis above is based on publicly available information and should not be the sole basis for any investment decision. Please consult a SEBI-registered financial advisor before making investment decisions.
Written by Avinash. Have a tip? Write to us at editorial@startupfeed.in.
